Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study.
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ administration & dosage
Dexamethasone
/ administration & dosage
Drug Implants
Female
Follow-Up Studies
Glucocorticoids
/ administration & dosage
Humans
Intravitreal Injections
Italy
Macula Lutea
/ diagnostic imaging
Male
Middle Aged
Recovery of Function
Retinal Vein Occlusion
/ diagnostic imaging
Retrospective Studies
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
/ drug effects
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
pubmed:
12
3
2021
medline:
11
2
2022
entrez:
11
3
2021
Statut:
ppublish
Résumé
Retinal vein occlusion is the second most common retinal vascular pathology after diabetic retinopathy and a major cause of vision impairment. Nowadays, both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) can be well-managed by intravitreal treatments. However, considering the long-life expectance of the patients, few data are present in the literature about the very long-term outcome of CRVO and BRVO. The present study was an interventional, retrospective analysis of the morphological and functional long-term outcome of CRVO and BRVO patients, followed in an Italian referral center. We collected data from 313 eyes (178 CRVO eyes and 135 BRVO eyes). Mean follow-up was 45 ± 25 months (range 12-84 months). Both CRVO and BRVO eyes experience a significant visual acuity improvement secondary to anti-vascular endothelial growth factor/dexamethasone treatments (from 0.57 ± 0.25 to 0.41 ± 0.24 LogMAR in CRVO and from 0.53 ± 0.42 to 0.30 ± 0.41 LogMAR in BRVO, respectively) (
Identifiants
pubmed: 33706397
doi: 10.1055/s-0041-1725197
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Drug Implants
0
Glucocorticoids
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1361-1366Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
F.B. consultant for: Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss (Dublin, USA). All other authors have no disclosures to declare.